NICE guidance on everolimus in combination with exemestane for treatment of advanced HER2-negative, hormone-receptor-positive breast cancer after endocrine therapy

Gespeichert in:

Autor*in:	Burke, Martyn J [verfasserIn] Garrett, Zoe George, Elisabeth Adler, Amanda I

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2013

Umfang:	2

Übergeordnetes Werk:	Enthalten in: My - Citovsky, Vitaly ELSEVIER, 2019, London
Übergeordnetes Werk:	volume:14 ; year:2013 ; number:11 ; pages:1049-1050 ; extent:2

Links:	Volltext

DOI / URN:	10.1016/S1470-2045(13)70406-6

Katalog-ID:	ELV027049272

Internformat


LEADER	01000caa a22002652 4500
001	ELV027049272
003	DE-627
005	20230623185216.0
007	cr uuu---uuuuu
008	180603s2013 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1016/S1470-2045(13)70406-6 \|2 doi
028	5	2	\|a GBV00000000000179A.pica
035			\|a (DE-627)ELV027049272
035			\|a (ELSEVIER)S1470-2045(13)70406-6
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0		\|a 610
082	0	4	\|a 610 \|q DE-600
082	0	4	\|a 570 \|q VZ
084			\|a BIODIV \|q DE-30 \|2 fid
084			\|a 35.70 \|2 bkl
084			\|a 42.12 \|2 bkl
100	1		\|a Burke, Martyn J \|e verfasserin \|4 aut
245	1	0	\|a NICE guidance on everolimus in combination with exemestane for treatment of advanced HER2-negative, hormone-receptor-positive breast cancer after endocrine therapy
264		1	\|c 2013
300			\|a 2
336			\|a nicht spezifiziert \|b zzz \|2 rdacontent
337			\|a nicht spezifiziert \|b z \|2 rdamedia
338			\|a nicht spezifiziert \|b zu \|2 rdacarrier
700	1		\|a Garrett, Zoe \|4 oth
700	1		\|a George, Elisabeth \|4 oth
700	1		\|a Adler, Amanda I \|4 oth
773	0	8	\|i Enthalten in \|n The Lancet Publ. Group \|a Citovsky, Vitaly ELSEVIER \|t My \|d 2019 \|g London \|w (DE-627)ELV003173852
773	1	8	\|g volume:14 \|g year:2013 \|g number:11 \|g pages:1049-1050 \|g extent:2
856	4	0	\|u https://doi.org/10.1016/S1470-2045(13)70406-6 \|3 Volltext
912			\|a GBV_USEFLAG_U
912			\|a GBV_ELV
912			\|a SYSFLAG_U
912			\|a FID-BIODIV
912			\|a SSG-OLC-PHA
936	b	k	\|a 35.70 \|j Biochemie: Allgemeines \|q VZ
936	b	k	\|a 42.12 \|j Biophysik \|q VZ
951			\|a AR
952			\|d 14 \|j 2013 \|e 11 \|h 1049-1050 \|g 2
953			\|2 045F \|a 610

Indexfelder

author_variant	m j b mj mjb
matchkey_str	burkemartynjgarrettzoegeorgeelisabethadl:2013----:ieudnenvrlmsnobntowteeetnfrramnoavnehrngtvhroeeetroi
hierarchy_sort_str	2013
bklnumber	35.70 42.12
publishDate	2013
allfields	10.1016/S1470-2045(13)70406-6 doi GBV00000000000179A.pica (DE-627)ELV027049272 (ELSEVIER)S1470-2045(13)70406-6 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Burke, Martyn J verfasserin aut NICE guidance on everolimus in combination with exemestane for treatment of advanced HER2-negative, hormone-receptor-positive breast cancer after endocrine therapy 2013 2 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Garrett, Zoe oth George, Elisabeth oth Adler, Amanda I oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:14 year:2013 number:11 pages:1049-1050 extent:2 https://doi.org/10.1016/S1470-2045(13)70406-6 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 14 2013 11 1049-1050 2 045F 610
spelling	10.1016/S1470-2045(13)70406-6 doi GBV00000000000179A.pica (DE-627)ELV027049272 (ELSEVIER)S1470-2045(13)70406-6 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Burke, Martyn J verfasserin aut NICE guidance on everolimus in combination with exemestane for treatment of advanced HER2-negative, hormone-receptor-positive breast cancer after endocrine therapy 2013 2 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Garrett, Zoe oth George, Elisabeth oth Adler, Amanda I oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:14 year:2013 number:11 pages:1049-1050 extent:2 https://doi.org/10.1016/S1470-2045(13)70406-6 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 14 2013 11 1049-1050 2 045F 610
allfields_unstemmed	10.1016/S1470-2045(13)70406-6 doi GBV00000000000179A.pica (DE-627)ELV027049272 (ELSEVIER)S1470-2045(13)70406-6 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Burke, Martyn J verfasserin aut NICE guidance on everolimus in combination with exemestane for treatment of advanced HER2-negative, hormone-receptor-positive breast cancer after endocrine therapy 2013 2 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Garrett, Zoe oth George, Elisabeth oth Adler, Amanda I oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:14 year:2013 number:11 pages:1049-1050 extent:2 https://doi.org/10.1016/S1470-2045(13)70406-6 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 14 2013 11 1049-1050 2 045F 610
allfieldsGer	10.1016/S1470-2045(13)70406-6 doi GBV00000000000179A.pica (DE-627)ELV027049272 (ELSEVIER)S1470-2045(13)70406-6 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Burke, Martyn J verfasserin aut NICE guidance on everolimus in combination with exemestane for treatment of advanced HER2-negative, hormone-receptor-positive breast cancer after endocrine therapy 2013 2 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Garrett, Zoe oth George, Elisabeth oth Adler, Amanda I oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:14 year:2013 number:11 pages:1049-1050 extent:2 https://doi.org/10.1016/S1470-2045(13)70406-6 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 14 2013 11 1049-1050 2 045F 610
allfieldsSound	10.1016/S1470-2045(13)70406-6 doi GBV00000000000179A.pica (DE-627)ELV027049272 (ELSEVIER)S1470-2045(13)70406-6 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Burke, Martyn J verfasserin aut NICE guidance on everolimus in combination with exemestane for treatment of advanced HER2-negative, hormone-receptor-positive breast cancer after endocrine therapy 2013 2 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Garrett, Zoe oth George, Elisabeth oth Adler, Amanda I oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:14 year:2013 number:11 pages:1049-1050 extent:2 https://doi.org/10.1016/S1470-2045(13)70406-6 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 14 2013 11 1049-1050 2 045F 610
language	English
source	Enthalten in My London volume:14 year:2013 number:11 pages:1049-1050 extent:2
sourceStr	Enthalten in My London volume:14 year:2013 number:11 pages:1049-1050 extent:2
format_phy_str_mv	Article
bklname	Biochemie: Allgemeines Biophysik
institution	findex.gbv.de
dewey-raw	610
isfreeaccess_bool	false
container_title	My
authorswithroles_txt_mv	Burke, Martyn J @@aut@@ Garrett, Zoe @@oth@@ George, Elisabeth @@oth@@ Adler, Amanda I @@oth@@
publishDateDaySort_date	2013-01-01T00:00:00Z
hierarchy_top_id	ELV003173852
dewey-sort	3610
id	ELV027049272
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV027049272</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623185216.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2013 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1470-2045(13)70406-6</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000179A.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV027049272</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1470-2045(13)70406-6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.70</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">42.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Burke, Martyn J</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">NICE guidance on everolimus in combination with exemestane for treatment of advanced HER2-negative, hormone-receptor-positive breast cancer after endocrine therapy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">2</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Garrett, Zoe</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">George, Elisabeth</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Adler, Amanda I</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">The Lancet Publ. Group</subfield><subfield code="a">Citovsky, Vitaly ELSEVIER</subfield><subfield code="t">My</subfield><subfield code="d">2019</subfield><subfield code="g">London</subfield><subfield code="w">(DE-627)ELV003173852</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:14</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:11</subfield><subfield code="g">pages:1049-1050</subfield><subfield code="g">extent:2</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1470-2045(13)70406-6</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.70</subfield><subfield code="j">Biochemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">42.12</subfield><subfield code="j">Biophysik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">14</subfield><subfield code="j">2013</subfield><subfield code="e">11</subfield><subfield code="h">1049-1050</subfield><subfield code="g">2</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
author	Burke, Martyn J
spellingShingle	Burke, Martyn J ddc 610 ddc 570 fid BIODIV bkl 35.70 bkl 42.12 NICE guidance on everolimus in combination with exemestane for treatment of advanced HER2-negative, hormone-receptor-positive breast cancer after endocrine therapy
authorStr	Burke, Martyn J
ppnlink_with_tag_str_mv	@@773@@(DE-627)ELV003173852
format	electronic Article
dewey-ones	610 - Medicine & health 570 - Life sciences; biology
delete_txt_mv	keep
author_role	aut
collection	elsevier
remote_str	true
illustrated	Not Illustrated
topic_title	610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl NICE guidance on everolimus in combination with exemestane for treatment of advanced HER2-negative, hormone-receptor-positive breast cancer after endocrine therapy
topic	ddc 610 ddc 570 fid BIODIV bkl 35.70 bkl 42.12
topic_unstemmed	ddc 610 ddc 570 fid BIODIV bkl 35.70 bkl 42.12
topic_browse	ddc 610 ddc 570 fid BIODIV bkl 35.70 bkl 42.12
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	zu
author2_variant	z g zg e g eg a i a ai aia
hierarchy_parent_title	My
hierarchy_parent_id	ELV003173852
dewey-tens	610 - Medicine & health 570 - Life sciences; biology
hierarchy_top_title	My
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)ELV003173852
title	NICE guidance on everolimus in combination with exemestane for treatment of advanced HER2-negative, hormone-receptor-positive breast cancer after endocrine therapy
ctrlnum	(DE-627)ELV027049272 (ELSEVIER)S1470-2045(13)70406-6
title_full	NICE guidance on everolimus in combination with exemestane for treatment of advanced HER2-negative, hormone-receptor-positive breast cancer after endocrine therapy
author_sort	Burke, Martyn J
journal	My
journalStr	My
lang_code	eng
isOA_bool	false
dewey-hundreds	600 - Technology 500 - Science
recordtype	marc
publishDateSort	2013
contenttype_str_mv	zzz
container_start_page	1049
author_browse	Burke, Martyn J
container_volume	14
physical	2
class	610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl
format_se	Elektronische Aufsätze
author-letter	Burke, Martyn J
doi_str_mv	10.1016/S1470-2045(13)70406-6
dewey-full	610 570
title_sort	nice guidance on everolimus in combination with exemestane for treatment of advanced her2-negative, hormone-receptor-positive breast cancer after endocrine therapy
title_auth	NICE guidance on everolimus in combination with exemestane for treatment of advanced HER2-negative, hormone-receptor-positive breast cancer after endocrine therapy
collection_details	GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA
container_issue	11
title_short	NICE guidance on everolimus in combination with exemestane for treatment of advanced HER2-negative, hormone-receptor-positive breast cancer after endocrine therapy
url	https://doi.org/10.1016/S1470-2045(13)70406-6
remote_bool	true
author2	Garrett, Zoe George, Elisabeth Adler, Amanda I
author2Str	Garrett, Zoe George, Elisabeth Adler, Amanda I
ppnlink	ELV003173852
mediatype_str_mv	z
isOA_txt	false
hochschulschrift_bool	false
author2_role	oth oth oth
doi_str	10.1016/S1470-2045(13)70406-6
up_date	2024-07-06T20:57:28.327Z
_version_	1803864714329980928
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV027049272</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623185216.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2013 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1470-2045(13)70406-6</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000179A.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV027049272</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1470-2045(13)70406-6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.70</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">42.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Burke, Martyn J</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">NICE guidance on everolimus in combination with exemestane for treatment of advanced HER2-negative, hormone-receptor-positive breast cancer after endocrine therapy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">2</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Garrett, Zoe</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">George, Elisabeth</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Adler, Amanda I</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">The Lancet Publ. Group</subfield><subfield code="a">Citovsky, Vitaly ELSEVIER</subfield><subfield code="t">My</subfield><subfield code="d">2019</subfield><subfield code="g">London</subfield><subfield code="w">(DE-627)ELV003173852</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:14</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:11</subfield><subfield code="g">pages:1049-1050</subfield><subfield code="g">extent:2</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1470-2045(13)70406-6</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.70</subfield><subfield code="j">Biochemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">42.12</subfield><subfield code="j">Biophysik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">14</subfield><subfield code="j">2013</subfield><subfield code="e">11</subfield><subfield code="h">1049-1050</subfield><subfield code="g">2</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
score	7.4006424

Nicht das Richtige dabei?

Schreiben Sie uns!

NICE guidance on everolimus in combination with exemestane for treatment of advanced HER2-negative, hormone-receptor-positive breast cancer after endocrine therapy

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?